Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines
Clinical Infectious Diseases·
- DOI
- 10.1093/cid/civ609
- PMID
- 26409271
- PMCID
- PMC4583570
- OpenAlex
- W2316878588
- Study type
- Journal article
- Publisher
- Oxford University Press (OUP)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The article characterizes tuberculosis as a continuing global emergency and identifies early rapid diagnosis, shorter treatment, improved outcomes, and prevention as urgent areas for innovation and sustained political and funding commitment.
Structured evidence summary
Research question
The article summarizes the status and prospects of advances in tuberculosis diagnostics, drugs, and vaccines, including priorities for improving diagnosis, treatment duration, outcomes, and prevention.
Study design
This is a peer-reviewed journal perspective or review article based on its title, article type, and abstract framing. The supplied material does not describe a primary research cohort, experiment, or formal systematic-review method.
Population and setting
The discussion concerns tuberculosis globally, with specific attention to multidrug-resistant and extensively drug-resistant tuberculosis and tuberculosis occurring with HIV infection or noncommunicable diseases.
Main findings
The abstract describes promising diagnostic approaches, including nucleic acid amplification, imaging, and breath analysis, and reports ongoing development and clinical evaluation of new or repurposed drug regimens for drug-resistant tuberculosis. It states that no new tuberculosis vaccine candidates had entered clinical testing since the reported MVA85A vaccine failure two years earlier, while treatment duration and outcomes for drug-resistant tuberculosis and relevant comorbidities remained unsatisfactory.
Public-health relevance
The article characterizes tuberculosis as a continuing global emergency and identifies early rapid diagnosis, shorter treatment, improved outcomes, and prevention as urgent areas for innovation and sustained political and funding commitment.
Important limitations
No explicit study limitations are provided in the supplied abstract. This summary is limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade assessment of methods, evidence selection, quantitative support, and applicability.
GIDS interpretation
The supplied classifier links make the article discoverable in contexts involving tuberculosis, AIDS, antimicrobial resistance, diagnostics, treatment, and vaccination. They provide topic context only and do not establish or confirm a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.